Inhibikase Therapeutics, Inc. (IKT)
2.43
0.00 (0.00%)
USD |
NASDAQ |
Sep 09, 11:41
Inhibikase Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.0005 |
| March 31, 2025 | 0.0009 |
| December 31, 2024 | 0.0012 |
| September 30, 2024 | -0.2737 |
| June 30, 2024 | 0.0349 |
| March 31, 2024 | 0.0309 |
| December 31, 2023 | 0.0567 |
| September 30, 2023 | 0.018 |
| June 30, 2023 | 0.0153 |
| March 31, 2023 | 0.0128 |
| December 31, 2022 | 0.0167 |
| September 30, 2022 | 0.0149 |
| June 30, 2022 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.0065 |
| September 30, 2021 | 0.0058 |
| June 30, 2021 | 0.0053 |
| March 31, 2021 | 0.1548 |
| December 31, 2020 | 0.0326 |
| September 30, 2020 | |
| June 30, 2020 | -0.1386 |
| March 31, 2020 | -0.1396 |
| December 31, 2019 | -0.0833 |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | -0.3004 |
| March 31, 2018 | -0.3176 |
| December 31, 2017 | -0.3192 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
| Anika Therapeutics, Inc. | 0.1839 |
| Savara, Inc. | 0.2117 |
| Vericel Corp. | 0.2556 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 163.59M |
| Total Liabilities (Quarterly) | 10.26M |
| Shareholders Equity (Quarterly) | 153.33M |
| Current Ratio | 15.82 |
| Net Debt Paydown Yield | 0.01% |